シスプラチン投与後の血清クレアチニン値上昇に関する調査:―ハイドレーションの組成と患者背景が及ぼす影響―
スポンサーリンク
概要
- 論文の詳細を見る
Cisplatin is a platinum compound used in solid tumor treatment. A dose limiting factor in cisplatin treatment is renal function disorder. Hydration is performed as a precaution at the time of cisplatin dosage. However, a most appropriate hydration method has yet to be established. Therefore, we investigated the serum creatinine rise in patients after cisplatin therapy to clarify an effective hydration method and risk factors of renal function disorder. We administered the treatment of 266 cycles in 111 patients who had received chemotherapy including more than 60 mg/m2 cisplatin in the past. We investigated the infusion solution used for hydration, various patient criteria factors and serum creatinine changes before and after cisplatin dosage. As a result, no significant difference was recognized in age, sex, diuretic dosage, and treatment cycles. However, a significant difference in the ratio of the patients was seen in those whose serum creatinine level increased at an Na load less than 371 mEq (odds ratio: 3.141, 95% confidence interval: 1.174-8.407, p=0.017), whose serum creatinine before the treatment was at more than 85.5% of the normal range upper limit value (4.481, 1.310-15.317, 0.012) and whose cisplatin dose was more than 60.1 mg/m2 (3.565, 1.117-12.493, 0.041). We infer that these are risk factors for a serum creatinine rise with the cisplatin treatment. Providing Na in excess of 371 mEq in hydration seems to be an effective precaution of the renal function disorder.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)